Anemia Management in Dialysis Patients Flashcards

What is the primary mechanism by which erythropoiesis-stimulating agents (ESAs) treat anemia in dialysis patients?

Answer: Binding to EPO receptors on erythroid progenitors to stimulate red blood cell production

ESAs bind to erythropoietin receptors on bone marrow erythroid progenitor cells, triggering proliferation and differentiation into mature red blood cells, replacing the EPO the diseased kidneys can no longer produce.

Which of the following best describes functional iron deficiency in dialysis patients?

Answer: Normal or elevated ferritin with low TSAT indicating inadequate iron mobilization

Functional iron deficiency occurs when iron stores appear adequate (normal/high ferritin) but iron cannot be mobilized rapidly enough to meet the demands of ESA-stimulated erythropoiesis, resulting in a low TSAT.

A large clinical trial (TREAT) showed that targeting hemoglobin levels above 13 g/dL with ESA therapy in CKD patients significantly increased the risk of which adverse outcome?

Answer: Stroke and cardiovascular events

The TREAT trial demonstrated a significantly increased risk of stroke when darbepoetin alfa was used to target near-normal hemoglobin (≥13 g/dL), establishing that higher hemoglobin targets are harmful in this population.

A dialysis patient has Hgb 9.6 g/dL, TSAT 26%, and ferritin 680 ng/mL while receiving ESA therapy. What is the most appropriate next step?

Answer: Investigate other causes of anemia such as occult bleeding, folate/B12 deficiency, or inflammation

With TSAT >20% and ferritin >500 ng/mL, iron deficiency is not the likely cause; the nurse should work with the provider to investigate other contributors such as GI blood loss, nutritional deficiencies, infection, or aluminum toxicity.

Which diagnostic test is used to confirm the presence of anti-erythropoietin antibodies when pure red cell aplasia (PRCA) is suspected in a dialysis patient?

Answer: Anti-EPO antibody assay (ELISA)

An anti-EPO antibody assay (ELISA) detects neutralizing antibodies against erythropoietin to confirm the diagnosis of PRCA; bone marrow biopsy showing absent erythroid precursors is also required for definitive diagnosis.

Which of the following nutritional deficiencies, when present in a dialysis patient, can blunt the response to ESA therapy by impairing DNA synthesis in erythroid precursors?

Answer: Vitamin B12 (cobalamin) deficiency

Vitamin B12 deficiency impairs DNA synthesis via its role in the methionine–folate cycle; without adequate B12, erythroid precursors cannot proliferate effectively, reducing the bone marrow's response to ESA stimulation.

During hemodialysis, a nurse notes the patient's blood in the extracorporeal circuit appears unusually dark. The patient denies symptoms. The hemoglobin drawn pre-treatment was 11.2 g/dL. What is the most likely explanation?

Answer: Adequate hemoglobin with normal venous oxygen saturation

Dark venous blood returning through the extracorporeal circuit is normal; it reflects deoxygenated venous blood with a hemoglobin of 11.2 g/dL, which is within acceptable target range for a dialysis patient.